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Abstract
Background: HIV adherence to erythrocytes has been demonstrated in vitro, and it has been suggested that erythrocytes
may be carriers of the virus. However, the association between HIV particles or viral proteins and erythrocytes in HIV-
infected individuals is still to be elucidated.
Methodology/Principal Findings: HIV-positive participants (n=112) were classified into two groups according to values of
three plasma viral loads (pVL) determined during the 12-month period prior to the study. The first group included 71
individuals with detectable pVL, whereas the second group included 41 individuals with undetectable pVL. Plasma viral
load, erythrocyte-associated p24-antigen and p24-antigen in plasma were determined at the moment of the study. A total
of 51 out of the 71 patients with detectable pVL showed erythrocyte-associated p24-antigen whereas 13 showed p24-anti-
gen in plasma. Twenty-two out of the 51 patients with erythrocyte-associated p24-antigen showed pVL,10,000 copies/ml
and undetectable p24-antigen in plasma. The data indicates that the amount of erythrocyte-associated p24-antigen was not
related to p24-antigen in plasma or pVL levels in this group. Among the 41 patients with prior undetectable pVL, eight
presented detectable pVL and erythrocyte-associated p24-antigen at the moment of the study. The other 33 showed
undetectable pVL and five of these presented erythrocyte-associated p24-antigen. A positive relationship was found
between the presence of erythrocyte-associated p24-antigen and the detectable pVL at the moment of the study
(p,0.00001). Even more, in another series of assays, a detectable viral load associated to erythrocytes was determined and it
was always accompanied by erythrocyte-associated p24-antigen detection.
Conclusions/Significance: This study demonstrates the presence of erythrocyte-associated p24-antigen in HIV-infected
individuals. Since erythrocyte-associated p24-antigen is not always related to pVL or p24-antigen in plasma, erythrocyte-
associated p24-antigen showed viral expression not represented in plasma. Therefore, the determination of erythrocyte-
associated p24-antigen may contribute to better understand the kinetics and/or evolution of HIV infection.
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Introduction
The concept of immune-adherence to describe the antibody- and
complement-mediated binding of bacteria to erythrocytes was
introduced by Nelson in 1953 [1]. Immune complexes, namely
antigens opsonized by antibodies and complement, are bound to
erythrocytes through specific interactions of the complement protein
C3b with the erythrocyte complement receptor 1 (CR1 or CD35) in
the erythrocyte membrane. Erythrocytes carried in the bloodstream
pass through the spleen and liver where macrophages take up the
immune complexes [2,3]. During persistent chronic viral infections,
simultaneous antibody and virus production occurs, creating the
conditions for the formation of immune complexes and the
subsequent erythrocyte adherence. However, erythrocyte-associated
antigen is not usually examined in chronic viral infections.
Human immunodeficiency virus type 1 (HIV) particles are
known to be capable of binding to erythrocytes in vitro by at least
three mechanisms: 1) immune complexes may bind to the CR1
receptor by means of complement proteins, 2) HIV may bind to
CR1 on the erythrocyte membrane by means of complement
proteins in the absence of antibodies, and 3) HIV can bind to
Duffy antigen receptor for chemokines (CD55 or DARC) present
in erythrocytes. This binding of HIV to erythrocytes in vitro needs
the presence of Ca
2+/Mg
2+ [4–7]. It has been observed that HIV-
positive individuals show increased C3 activation and decreased
number of CR1 on erythrocyte membranes [8,9]. This is likely
evidence of the immune adherence in vivo. Erythrocyte-associated
HIV may play an important role as an intermediary of infection of
T lymphocytes, monocytes, macrophages from spleen and liver
and other susceptible cells [6,7,10–12].
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erythrocytes in HIV-infected individuals is still to be elucidated.
To date, only two studies on erythrocyte-associated HIV RNA in
infected individuals have been published, with controversial
conclusions. In the first study, HIV RNA bound to erythrocytes
was observed in HIV-positive individuals even in some with
undetectable plasma viral load (pVL) during highly active
antiretroviral therapy (HAART) [11]; in the second study,
erythrocyte-associated HIV RNA was not found in the group of
individuals under HAART [13]. These two studies did not take
into account the possible presence of free viral antigen regardless
of the presence of viral particles. The presence of p24-antigen in
HIV infection is a marker of viral expression. Consequently,
assessment of viral antigens may provide important information on
follow-up and infection evolution.
The aim of this work was to study erythrocyte-associated viral
antigen in HIV-positive individuals at different stages of the
infection. Here we present evidence indicating that erythrocyte-
associated p24-antigen (Ag-E) is present in HIV-positive individ-
uals even in some with undetectable p24-antigen or viral load in
plasma. Indeed the presence of Ag-E was not always related to the
pVL or p24-antigen in plasma. The study of HIV bound to
erythrocytes is important in order to improve our understanding of
the kinetics of HIV infection and because of its potential usefulness
as a tool for the follow-up of patients.
Results
p24-antigen is detected in erythrocytes of HIV-positive
individuals
In order to search for p24-antigen in purified erythrocytes from
HIV-positive individuals, samples of 71 individuals with detectable
pVL ($50 copies per ml) in at least one sample during the year
prior to the study were used. Ag-E was found in 71.8% (51/71) of
the individuals, whereas p24-antigen in plasma (Ag-P) was found
only in 18.3% (13/71) of them. Examination of possible
combinations between Ag-E and Ag-P showed the presence of
Ag-E with no Ag-P in 56.3% (40/71) of HIV-positive individuals,
absence of both Ag-E and Ag-P in 25.4% (18/71) and presence of
both in 15.5% (11/71). Only 2.8% of patients (2/71) showed
presence of Ag-P in the absence of Ag-E (Table 1). In all cases the
median and interquartile range (IQR) were calculated considering
only detectable values. A median level of 41 pg p24-antigen/ml
was found in purified erythrocytes (IQR 21–121). In plasma,
median values of p24-antigen were 148 pg/ml (IQR 105–152).
In addition, we found pVL,10,000 copies/ml in 32 out of the
71 patients evaluated and pVL$10,000 copies/ml in the
remaining 39. No p24-antigen in plasma was detected in any of
the 32 individuals with pVL,10,000 copies/ml, while Ag-E was
detected in 22 out of these 32 individuals. Indeed, four out of these
22 individuals presented pVL,50 copies/ml, and three out of
these four exhibited Ag-E levels above 110 pg p24-antigen/ml.
Eleven out of the 39 individuals with pVL$10,000 copies/ml
presented both Ag-E and Ag-P, whereas two showed absence of
Ag-E and presence of Ag-P and 18 showed presence of Ag-E
without detectable Ag-P. Finally, p24-antigen was not detected at
all in the remaining eight individuals (Table 1). To note, eight out
of the 13 cases where Ag-P was detectable showed higher levels of
Ag-P than of Ag-E (Table 1).
It is important to highlight that p24-antigen was never detected
in the supernatant of the last wash of purified erythrocytes (see
Methods section), showing that Ag-E determination was not
affected by Ag-P.
With the aim to elucidate the relationship between pVL and the
presence of Ag-E and Ag-P, the 71 individuals studied were
assigned to four groups according to their pVL at the moment of
the study: 1) ,1,000 copies/ml (n=20), 2) 1,000–9,999 copies/ml
(n=12), 3) 10,000–49,999 copies/ml (n=21), 4) $50,000 copies/
ml (n=18), and the percentage of individuals with p24-antigen
detection in plasma and in erythrocytes was evaluated (Figure 1).
As expected, there was a significant positive relationship between
the different groups of pVL and the presence of Ag-P (p,0.0001),
where Ag-P was related to higher pVL, being detectable in
individuals with pVL$10,000 copies/ml (p,0.0001). To note,
Ag-P was not always detected in individuals with pVL$10,000
copies/ml. On the other hand, a high proportion of individuals
(more than 50% in every group) presented Ag-E regardless of their
pVL (p=0.68). Moreover, no relationship was observed between
the presence of Ag-E and Ag-P as reported above (Table 1).
In summary, these results demonstrate the existence of Ag-E in
HIV-positive individuals. Moreover, the presence of p24-antigen
in erythrocytes was not necessarily related to Ag-P or pVL, even in
those patients with pVL,10,000 copies/ml and absence of Ag-P.
Ag-E was present in more than 50% of these cases.
p24-antigen associated to erythrocytes was detected in
HIV-positive individuals with undetectable plasma viral
load for one year
After demonstrating the presence of p24-antigen in purified
erythrocytes from HIV-positive individuals, it was important to
note that we found this Ag-E in patients with pVL,1,000 copies/
ml at the moment of the study. Therefore, we wondered whether
Ag-E might also be detected in individuals with undetectable pVL
for one year prior to the study. To this end, we used 41 samples
from HIV-positive individuals with undetectable pVL in three
determinations for 12 months before the study. Eight out of the 41
individuals showed detectable pVL (median: 112 copies/ml; IQR
77–403) at the moment of the study and all of them presented Ag-
E (median: 25 pg p24-antigen/ml; IQR 20–76) (Table 2). In
contrast, 33 out of the 41 individuals presented undetectable pVL
at the moment of the study, and five out of these 33 showed Ag-E
(median: 38 pg p24-antigen/ml; IQR 31–97). When analyzing
both groups, a significant positive relationship between detectable
pVL and the presence of Ag-E was found (p,0.00001) (Table 2).
p24-antigen was not detected in plasma of any sample or in the
supernatant of the last wash of each sample of purified
erythrocytes from the 41 individuals.
These results show that Ag-E was present in individuals with
undetectable pVL for one year. Furthermore, pVL detection at the
moment of the study is related to the presence of Ag-E, suggesting
that Ag-E determination could be a possible indicator for viral
expression.
Erythrocyte-associated p24-antigen quantification is
independent of the erythrocyte purification method
used
With the aim to determine whether the quantification of Ag-E
depends on the purification method used, erythrocyte-enriched
fractions from 27 HIV-positive individuals were divided into two
aliquots. One aliquot was purified by dextran sedimentation while
the other was purified by magnetic bead depletion (magnetic beads
coated with antibodies to CD4 and CD8). By dextran sedimen-
tation, samples were depleted of leukocytes in 93.6% as compared
to whole blood (median residual leukocytes: 175/ml; median
residual lymphocytes: 58/ml; median residual CD3+ CD4+
lymphocytes: 27/ml). On the other hand, the leukocyte depletion
Erythrocytes and p24-Antigen
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(median residual leukocytes: 100/ml; median residual lymphocytes:
11/ml; median residual CD3+ CD4+ lymphocytes: 3/ml). The
maximum Ag-E difference between both procedures was 21.0%,
with a mean value of 5.0%. Linear regression between the Ag-E
levels obtained by dextran sedimentation and those obtained by
magnetic bead depletion showed an R
2 of 0.981 and a slope of
0.972. Ag-E was detectable by both techniques in 17 samples,
whereas it was undetectable by both techniques in other 10
samples. Besides, in erythrocyte-enriched fractions of six samples
Table 1. Plasma viral load and p24-antigen in plasma and erythrocytes from individuals with detectable plasma viral load in at
least one sample during the year prior to the study.
HIV-positive
individuals pVL (copies/ml) Ag-E (pg/ml) Ag-P (pg/ml)
HIV-positive
individuals pVL (copies/ml) Ag-E (pg/ml) Ag-P (pg/ml)
1 ,50 .152 NR 36 13,888 NR NR
2 ,50 .152 NR 37 14,293 NR NR
3 ,50 NR NR 38 16,334 134.48 NR
4 ,50 112.4 NR 39 17,489 24.88 NR
5 53 NR NR 40 17,781 29.93 NR
66 7,20
* NR 41 18,188 28.08 NR
76 8,20
* NR 42 19,522 21 NR
87 6.152 NR 43 22,061 NR NR
98 3,20
* NR 44 22,217 126 .152
10 90.6 97.36 NR 45 25,334 117.6 NR
11 104 NR NR 46 27,478 NR 148
12 109 NR NR 47 30,585 33 NR
13 126 34.52 NR 48 31,627 NR NR
14 131 ,20
* NR 49 39,441 ,20
* NR
15 131 .152 NR 50 41,687 21.64 40
16 135 NR NR 51 45,594 97.2 NR
17 144 .152 NR 52 46,347 NR NR
18 175 ,20
* NR 53 48,125 33.16 NR
19 398 ,20
* NR 54 50,394 ,20
* NR
20 479 30.4 NR 55 51,107 30 NR
21 1,389 ,20
* NR 56 62,679 NR NR
22 1,406 103.2 NR 57 100,928 .152 .152
23 1,603 NR NR 58 155,010 57 NR
24 1,720 ,20
* NR 59 160,981 27.2 90
25 2,048 NR NR 60 198,000 121.12 .152
26 3,087 NR NR 61 247,521 61 127.17
27 3,966 ,20
* NR 62 261,100 NR NR
28 4,133 20.72 NR 63 316,443 107.2 NR
29 4,445 60.72 NR 64 380,691 37.76 NR
30 5,207 NR NR 65 426,691 NR NR
31 9,031 59 NR 66 .500,000 45.08 126
32 9,329 NR NR 67 .500,000 NR 120
33 11,422 41 NR 68 .500,000 .152 .152
34 12,855 23.04 NR 69 .500,000 .152 NR
35 13,100 103.6 34.4 70 .500,000 .152 .152
71 .500,000 .152 .152
Median 41 148
IQR 21–121 105–152
pVL: plasma viral load at the moment of the study.
Ag-E (pg/ml): pg erythrocytes-associated p24-antigen per milliliter of purified erythrocytes.
Ag-P (pg/ml): pg p24-antigen per milliliter in plasma.
NR: non reactive.
Median: median was calculated having in mind the detectable values.
IQR: interquartile range. In all cases used, IQR was calculated considering only detectable values.
*: this value was considered positive because it was under 20 pg but over the cut-off (value,20).
doi:10.1371/journal.pone.0014544.t001
Erythrocytes and p24-Antigen
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using anti-CD3 antibodycoated beads, a leukocyte depletion of 99%
was observed. Three out of these six samples showed detectable pVL
and an Ag-E higher than 152 pg/ml, while the other three had
neither pVL nor Ag-E. Therefore, these experiments suggest that
determination of p24-antigen on erythrocytes yields comparable
results regardless of the purification method used.
Contaminating leukocytes are not significant sources of
p24-antigen in purified erythrocytes
In order to elucidate whether residual leukocytes from purified
erythrocytes were significant sources of p24-antigen, leukocytes
(Leukocytes HIV+) and erythrocytes (E HIV+) from seven HIV-
positive individuals with detectable Ag-E were obtained by dextran
sedimentation. The residual leukocytes of each sample were
quantified in purified erythrocytes. Then, the same amount of
quantified contaminant leukocytes was mixed with erythrocytes
from HIV-negative individuals (Leukocytes HIV+ + E HIV2).
Subsequently, both samples from each individual, (E HIV+)a n d
(Leukocytes HIV+ + E HIV2), were subjected to p24-antigen de-
termination as described in the Methods section. No p24-antigen
was detected in any of the Leukocytes HIV+ + E HIV2 samples, in
remarkable contrastwiththe E HIV+samples,whichwereallpositive
for p24-antigen detection (data not shown). All data presented here
indicate that if there is p24-antigen associated with residual
leukocytes, it is not a significant contributor to Ag-E determination.
A defined population of erythrocytes is responsible for
carrying the p24-antigen associated to their membranes
To further confirm that p24-antigen was really associated to the
erythrocyte membrane, we performed a p24-antigen immunoflu-
orescence in purified erythrocytes from 15 HIV-positive individ-
uals with pVL ranging from 1,000 to 20,000 copies/ml. Twelve
out of the 15 individuals presented a p24-antigen positive signal on
erythrocytes with a very similar pattern. Figure 2 shows positive
p24-antigen immunoreactivity on erythrocytes from three of the
12 positive patients. Erythrocytes from HIV-negative individuals
treated or not with tannic acid (positive controls) were able to bind
recombinant p24-antigen. In contrast, no fluorescence was
detected in purified erythrocytes from HIV-negative individuals
used as negative controls (Figure 2).
With the purpose of determining the proportion of erythrocytes
carrying p24-antigen, we performed flow-cytometry assays using a
FITC-conjugated p24-specific antibody. Erythrocytes of HIV-po-
sitive individuals with pVL between 1,000 and 20,000 copies/ml
showed a mean of p24-antigen-immunoreactive erythrocytes of
1464% (mean 6 SD) with a mean fluorescence of 3365 (mean 6
SD) (Figure 3A). It is interesting to note that p24-antigen was
associated to a defined erythrocyte population. Only background
or unspecific fluorescence was detected in the overall erythrocyte
population from HIV-negative individuals (Figure 3B).
In conclusion, these results demonstrate that p24-antigen is
associated to the membrane of erythrocytes within a defined
population of erythrocytes in HIV-positive individuals.
Viral load associated to erythrocytes is detected in HIV-
positive individuals with p24-antigen associated to
erythrocytes
The results shown so far reveal the presence of Ag-E in patients
with different pVL. This finding led us to wonder whether the
detection of p24-antigen on erythrocytes is related to viral HIV
Figure 1. p24-antigen associated to erythrocytes is not related
to plasma viral load. Seventy one individuals with detectable plasma
viral load (pVL) in at least one sample during the year before the study
were classified into four intervals according to their pVL at the moment
of the study: 1) ,1,000 copies/ml (n=20), 2) 1,000–9,999 copies/ml
(n=12), 3) 10,000–49,999 copies/ml (n=21) and 4) $50,000 copies/ml
(n=18). Bars represent percentages of subjects with p24-antigen
associated to erythrocytes (Ag-E, black bars) and p24-antigen in plasma
(Ag-P, white bars). In each of the first three intervals there is a significant
difference between the presence of Ag-E and Ag-P. No relationship is
observed between Ag-E and pVL among the different pVL intervals
(p=0.68). A significant relationship was found between pVL intervals
and the presence of Ag-P (p,0.0001). * p,0.001; ** p,0.0001.
doi:10.1371/journal.pone.0014544.g001
Table 2. p24-antigen associated to erythrocytes in
individuals with consecutive undetectable plasma viral load
for one year.
pVL
HIV-positive
individuals
pVL
(copies/ml)
Ag-E
(pg/ml)
Ag-P
(pg/ml)
Detectable 16 7 ,20* NR
N=8 27 6 .152 NR
38 3 ,20* NR
4 98 90.6 NR
5 126 34.52 NR
61 7 5 ,20* NR
7 479 30.4 NR
83 , 9 6 6 ,20* NR
Undetectable 9t o3 6 ,50 NR NR
N=33 37 ,50 30.4 NR
38 ,50 31.6 NR
39 ,50 38.0 NR
40 ,50 42.0 NR
41 ,50 .152 NR
pVL: plasma viral load at the moment of the study.
Undetectable pVL: plasma viral load ,50 copies per milliliter.
Detectable pVL: plasma viral load $50 copies per milliliter.
Ag-E (pg/ml): pg erythrocytes-associated p24-antigen per milliliter of purified
erythrocyte.
Ag-P (pg/ml): pg p24-antigen per milliliter in plasma.
NR: non reactive.
*: this value was considered positive because it was under 20 pg but over the
cut-off (value,20).
doi:10.1371/journal.pone.0014544.t002
Erythrocytes and p24-Antigen
PLoS ONE | www.plosone.org 4 January 2011 | Volume 6 | Issue 1 | e14544RNA in these cells. To clarify this issue viral load associated to
erythrocytes (eVL), pVL, and Ag-P were determined in 34 HIV-
positive individuals (10 with undetectable Ag-E and 24 with
detectable Ag-E). Table 3 shows that 8 out of the 10 patients with
undetectable Ag-E had no viral HIV RNA in plasma, or on
erythrocytes and no Ag-P. There were two patients with detectable
pVL but undetectable Ag-E, Ag-P and eVL. Results correspond-
ing to the individuals with detectable Ag-E showed that 7 out of
the 24 patients showed only Ag-E, being the only test that reflected
viral expression. Interestingly, three out of the Ag-E positive
individuals (patients 18, 19 and 20) were accompanied only by the
presence of eVL, showing that viral expression is reflected only in
erythrocytes (Table 3). Five individuals presented only Ag-E and
presence of pVL. Finally in nine of the patients with detectable Ag-
E, HIV RNA was found in both plasma and erythrocyte fractions.
Three out of these nine patients were the only ones with detectable
Ag-P, corresponding with the highest pVL.
Although it is unusual to find detectable p24-antigen in plasma
samples from patients with undetectable or very low pVL in the
erythrocyte fraction, Ag-E detection was possible with low
amounts of eVL. These results suggest that the presence of eVL
could be related to a detectable Ag-E.
Discussion
The presence of viral proteins in HIV infection is an evidence of
viral expression regardless of the presence of viral particles. There
are other sources of p24-antigen including degraded virions or
defective particles and those released by killed infected cells [14].
Consequently, assessment of viral antigens may provide important
information on infection evolution. In this direction, erythrocytes
could provide a good target to assay the presence of viral antigens.
Moreover, research on antigen and/or virus carried by erythro-
cytes may be relevant during HIV infection due to the large
number of circulating erythrocytes that would facilitate infection of
susceptible cells [6,7,10–12]. The present study reports the
presence, sometimes in high values, of p24-antigen associated to
erythrocytes in HIV-positive individuals, even in those with
undetectable pVL.
Using dextran sedimentation, Hess et al., 2002 [11] reported
detectable viral loads in purified erythrocytes in a group of patients
under HAART, while, in a similar work but using beads-mediated
CD3 depletion as an erythrocyte purification technique, Fierer
et al., 2007 [13] did not reach the same conclusion and suggested
that the results obtained by Hess and colleagues might arise from a
CD3+CD4+ lymphocyte contamination. However, in Fierer’s
study, the presence of HIV-RNA in CD3+ cells was not evaluated.
Here we present evidence that partly elucidates the controversy
about HIV association to erythrocytes in HIV-positive individuals.
Although the viral RNA detection assay is quite sensitive,
quantification of the p24 viral antigen allowed us to measure not
only the antigen from viral particles but also the free p24-antigen.
In order to determine whether p24-antigen is present in
erythrocytes of HIV-positive individuals, it was necessary to rule
out the presence of p24-antigen associated to other non-
erythrocyte cells or from traces of plasma in the purified
erythrocyte fraction. To rule out potential confounds arising from
the use of different purification methods [11,13], we compared the
efficiency of erythrocyte purification by dextran sedimentation and
by magnetic bead depletion. Our results showed that p24-antigen
quantification on erythrocytes was similar with the two method-
ologies. We included the use of CD8+ beads because Gulzar et al.,
2008 [15] reported a significantly higher proportion of cells with
expression of CD8+ HIV-1 (gag)+ rather than of CD4+ HIV-1
(gag)+ T-cells. Besides, we also tested purification by magnetic
bead depletion with antibodies to CD3 and detected high levels of
Ag-E. Even more, the same amount of residual leukocytes in
purified erythrocytes from HIV-positive individuals was not
capable of achieving that the p24-antigen detection in purified
erythrocytes from HIV-negative individuals be over the assay’s
cut-off. Therefore, we may state that measurement of p24-antigen
on purified erythrocytes is not due to contamination and is not
affected by the purification method chosen.
Horakova et al., 2004 [4] and Beck et al., 2009 [7] described
EDTA-mediated in vitro inhibition of HIV binding to erythrocytes
in the presence and absence of complement respectively. We
confirmed these results in our laboratory (data not shown). The
possible binding of antigen present in plasma to erythrocytes after
blood sample collection was prevented by the use of EDTA as
anti-coagulant. Moreover, since p24-antigen was not detected in
the last erythrocyte-purification wash, we discarded the possibility
that Ag-E originates from contamination of other cell types or
from plasma.
Among the 71 individuals with detectable pVL in at least one
sample during the year preceding the present study, a high
percentage (71.8%) showed Ag-E and the amounts of Ag-E varied
Figure 2. p24-antigen is associated to erythrocyte membrane in HIV-positive individuals. Purified erythrocytes from HIV-negative and
HIV-positive individuals were subjected to immunofluorescence with anti-p24 antibody. Homogeneous fluorescence in membrane is observed in
purified erythrocytes from HIV-positive individuals (the three images shown are representative of 12 different HIV-positive individuals with plasma
viral loads ranging from 1,000 to 20,000 copies/ml). Purified erythrocytes from HIV-negative individuals incubated with p24-antigen alone or p24-
antigen plus tannic acid were used as positive control. No positive fluorescence is observed in purified erythrocytes from HIV-negative individuals.
doi:10.1371/journal.pone.0014544.g002
Erythrocytes and p24-Antigen
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were not related to pVL values or to the presence and/or levels of
Ag-P. This can be explained by the possibility that erythrocytes of
each individual may have different virus adsorption capacities.
This is supported by a recent work where virus binds in vitro to
erythrocytes of HIV-negative individuals in a wide range of
absorption capacities [7]. Another possible explanation would be
given by the several factors that may vary in each HIV-positive
individual, for example, the presence of antibodies which can mask
the viral antigen, a different activity of complement factors as
shown by Taush et al., 1986 [8] (increased C3 activation in HIV-
positive individuals), different kinetics of viral clearance and/or the
amount of receptors available on the erythrocyte membrane [16].
Individuals with pVL,10,000 copies/ml (Table 1) showed
only Ag-E detectable and Ag-P undetectable, suggesting that the
erythrocytes of these individuals have the capacity of adsorbing a
great deal of the antigen produced. In contrast, individuals
presenting pVL$10,000 copies/ml presented Ag-P even in higher
quantities than Ag-E, suggesting that in these individuals viral
production may exceed adsorption capacity of erythrocytes,
allowing the virus to reach high values in plasma. This was the
case of the two individuals with undetectable Ag-E but with high
levels of p24-antigen in plasma. However, 18 individuals of this
group showed Ag-E and absence of Ag-P.
As regards the eight individuals with previous undetectable pVL
for 12 months who presented current detectable pVL at the
moment of the study, all of them also showed a positive detection
of erythrocyte-associated p24 antigen. As shown in Table 2, the
pVL in these individuals were relatively low, suggesting a possible
recent viral rebound, while the values of Ag-E were similar to
those found in patients with previous detectable pVL (Table 1). A
highly positive significant relationship was found between a first
detectable pVL after 12 months of undetectable pVL and the
presence of Ag-E. Our results suggest that the presence of Ag-E
could be caused by a rebound marker in pVL, suggesting that pVL
might be assessed during the follow-up of these patients only when
the antigen is present on erythrocytes, thus reducing monitoring
costs.
Eight of the individuals shown in Tables 1 and 2 (71 and 41
respectively) showed detectable Ag-E and undetectable pVL at the
moment of the study. In four of these, the Ag-E value was
.110 pg p24-antigen/ml. Considering that the circulating
erythrocytes have a mean life of 120 days, two or three rounds
of erythrocyte renewal should have taken place in them since the
last plasma RNA detection. Since p24-antigen and HIV RNA
were absent in the plasma of these individuals, the origin of Ag-E is
unknown. A possible explanation to this may be addressed by the
results of Schu ¨pbach et al., 2005 [17], who found a discrepancy
between the values of plasma viral antigen mass and pVL.
Moreover, most p24-antigen present in plasma from infected
patients cannot be pelleted [18], demonstrating that it is located
outside virus particles. This result has been confirmed in the
samples examined in our laboratory [19]. Schu ¨pbach et al., 2005
[17] postulated that p24-antigen may be derived from virus
Figure 3. p24-antigen is associated to a defined erythrocyte population. Representative flow-cytometry analysis of p24-antigen
immunostaining in purified erythrocytes is shown and side scatter (SSC) vs. FITC fluorescence is plotted. (A) Purified erythrocytes from HIV-positive
individuals and stained with anti-p24-FITC exhibited a mean value of 1464% p24-antigen-positive erythrocytes (mean fluorescence of 3365).
(B) Representative purified erythrocytes from HIV-negative individuals were stained with the anti-p24-FITC, and no specific stain in erythrocytes was
found. (C) Isotype control for HIV-positive purified erythrocytes. Inserts show the corresponding dot plot and region P1 represents FSC/SSC light-
scatter gate. Percentage of positive events is shown in the Q2 quadrant. Graphs are representative of seven independent experiments (for HIV-
positive experiments samples from individuals with plasma viral loads between 1,000 and 20,000 copies/ml were used).
doi:10.1371/journal.pone.0014544.g003
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that assumed by Schu ¨pbach et al., 2005 [17] and our results are
correct, it could be expected that Ag-E will be found in individuals
who show undetectable HIV RNA in plasma. Therefore, most of
the p24-antigen found in erythrocytes would be originated in viral
reservoirs, bound to erythrocytes, and remaining undetected in
plasma. Indeed, Ag-E could come from latently infected cells,
which, when stimulated, release virus to plasma, which is likely
adsorbed by erythrocytes [20]. Alternatively, erythrocytes in close
contact with liver and spleen macrophages could manage to
adsorb antigens from them. In addition, Prado et al., 2004 [21]
suggested that p24-antigen binding to erythrocytes in HIV-positive
individuals during treatment interruptions may explain the lack of
longitudinal intrapatient correlation between Ag-P and pVL levels.
Erythrocyte-associated p24-antigen would reflect continuous viral
replication even in patients with undetectable pVL.
In support of our findings, we also demonstrated the association
between p24-antigen and erythrocytes by immunofluorescence
and flow-cytometry in patients with lower or moderate pVL levels.
Our data indicate that Ag-E does not seem to be present in all
erythrocytes, since only 1464% erythrocytes showed positive p24-
antigen in flow cytometry assays (Figure 3). This last observation
may be partially explained by incomplete viral clearance in
erythrocytes recently associated to p24-antigen, or by heteroge-
neity in the number of receptors available.
Our studies reveal that the presence of Ag-E is not necessarily
associated with detectable eVL. However, the presence of eVL
was always accompanied by Ag-E detection. This fact, together
with the low eVL and pVL observed in some patients with
detectable Ag-E, suggests that p24-antigen detected in the
erythrocyte fraction is mostly not associated with viral particles.
This could be explained by the fact that the transfer of virus to
other cells and/or efficient viral clearance may contribute to
diminishing eVL [11,12]. Besides, eVL is detected in most of the
patients who have detectable pVL, as well as in patients with
undetectable pVL (Table 3).
The results presented in this study demonstrate the presence of
Ag-E in HIV-positive individuals by three different methods of
Table 3. Viral load associated to erythrocytes in HIV-positive individuals.
Ag-E HIV-positive individuals pVL (copies/ml) Ag-P (pg/ml) eVL (copies/ml) Ag-E (pg/ml)
Undetectable 1t o8 ,50 NR ,50 NR
N=10 9 2,060 NR ,50 NR
10 6,624 NR ,50 NR
Detectable 11 ,50 NR ,50 ,20*
N=24 12 ,50 NR ,50 ,20*
13 ,50 NR ,50 ,20*
14 ,50 NR ,50 ,20*
15 ,50 NR ,50 80
16 ,50 NR ,50 80
17 ,50 NR ,50 92
18 ,50 NR 74 28
19 ,50 NR 128 ,20*
20 ,50 NR 368 ,20*
21 150 NR ,50 ,20*
22 279 NR ,50 29
23 1,039 NR ,50 ,20*
24 1,131 NR ,50 ,20*
25 2,417 NR ,50 108
26 111 NR 215 96
27 1,326 NR 104 ,20*
28 2,672 NR 830 ,20*
29 11,581 NR 71 80
30 26,355 NR 64 104
31 45,032 NR 1,268 ,20*
32 52,340 96 235 80
33 .500,000 .152 3,823 ,20*
34 .500,000 .152 14,364 33
pVL: plasma viral load at the moment of the study.
Undetectable Ag-E: undetectable erythrocytes-associated p24-antigen.
Detectable Ag-E: detectable erythrocytes-associated p24-antigen.
Ag-E (pg/ml): pg erythrocytes-associated p24-antigen per milliliter of purified erythrocyte.
Ag-P (pg/ml): pg p24-antigen per milliliter in plasma.
NR: non reactive.
*: this value was considered positive because it was under 20 pg but over the cut-off (value,20).
doi:10.1371/journal.pone.0014544.t003
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cytometry) and that Ag-E is not always related to plasma viral
load or to p24-antigen in plasma. In addition, they show the
presence of an important amount of viral antigen associated to
erythrocytes in individuals undergoing different stages of infection,
even in those with undetectable plasma viral load. Finally, the
erythrocyte-associated antigen study has a significant potential as a
tool for elucidating HIV infection kinetics, evolution, and follow-
up of patients.
Materials and Methods
Study population
A total of 234 HIV-positive individuals older than 21 years of
age who attended the Argentinean National Reference Centre for
AIDS for pVL assessment were invited to participate in this study.
Sixty-two HIV-negative individuals were recruited as controls.
The protocol was approved by the local Ethics Committee of the
University of Buenos Aires and a written informed consent was
signed by each participant.
A total of 112 HIV-positive participants were classified into two
groups according to the values of pVL obtained in three
determinations during the 12-month period prior to the current
study. The first group included 71 individuals with pVL$50
copies/ml in at least one sample during that period. The second
group included 41 individuals with pVL,50 copies/ml in all the
samples obtained during the same period. Samples from other 34
HIV-positive individuals were used to determine the viral load
associated to erythrocytes (eVL), whereas samples from the
remaining 88 HIV-positive individuals were used as controls and
for other assays.
Sample processing
Samples were obtained by venous puncture using EDTA as
anti-coagulant. Erythrocytes were processed the day of blood
collection. Blood was centrifuged at 1,400 g for 10 minutes.
Plasma was stored for pVL and Ag-P determination. The buffy
coat was discarded. A volume of 1 ml of the erythrocyte-enriched
fraction was diluted 1/2 in PBS, followed by addition of Dextran
4% (MW 200,000–275,000) (Biochemical), mixed by inversion
and kept in vertical position for 30 minutes at RT. The
erythrocyte sediment was washed four times in PBS. In each
wash, the supernatant and interface layers were aspirated and
discarded. As control for the washing process, the supernatant of
the last erythrocyte wash (Ag-W) was stored to be used in p24-
antigen detection assays. After sedimentation, all procedures were
carried out at 4uC. The low temperature conditions allowed for a
p24-antigen recovery approximately 6-fold higher than that
obtained at RT (data not shown). Median final concentration of
erythrocytes in the purified fraction was 7.78 10
6 erythrocytes/ml
(IQR 7.24 10
6– 8.90 10
6). A ratio of one leukocyte per 44,000
erythrocytes was estimated.
Alternatively, erythrocyte-enriched fractions from 27 HIV-
positive individuals were purified using a mix of magnetic beads
coated with antibodies to CD4 and CD8 (BD Biosciences). The
same process was repeated using magnetic beads coated with
antibodies to CD3 (DYNAL) for 6 samples.
Erythrocyte-associated viral antigen release
Erythrocytes were subjected to acid treatment in order to
release erythrocyte-associated antigen. Then, 750ml glycine-HCl
buffer (pH 3.2) was added to 250ml of purified erythrocytes at RT
and centrifuged at 470g for 5 minutes. The supernatant was
neutralized to pH 7.2 with NaOH 0.1N and kept at 220uC. The
glycine-HCl treatment was also performed in plasma and in the
supernatant of the last wash (Ag-W) of each sample as a control of
erythrocyte washing. p24-antigen was assessed in all fractions.
In order to determine whether the acid treatment affects p24-
antigen detection assays, purified erythrocytes from HIV-negative
individuals were incubated with a known amount of recombinant
p24-antigen and subjected to the glycine-HCl treatment under the
same conditions. The acid treatment did not affect p24-antigen
measurements (data not shown).
p24-antigen determination
p24-antigen was quantified by ELISA (Murex HIV antigen
Mab, Abbott). Cut-off calculation: a) Ag-P: according to the
manufacturer; b) Ag-E: average absorbance obtained after glycine-
HCl treatment of purified erythrocytes from 15 HIV-negative
individuals plus two Standard Deviations (SD); c) Ag-W: average
absorbance of supernatants obtained from Ag-W glycine-HCl
buffer treatment of 15 HIV-negative individuals plus two SD. The
detection limit for ELISA assay was 5 pg p24-antigen. For
quantification, the minimum required was 5 pg p24-antigen in
plasma and 20 pg for Ag-E.
Viral load determination
Plasma viral load was assessed by branched DNA (b-DNA)
technology, with a detection limit of 50 HIV-1 RNA copies/ml
(Versant HIV-1 RNA 3.0, Siemens Healthcare Diagnostics Inc.,
Tarrytown, NY). For measurement of erythrocyte-associated HIV
load, RNA extraction from one milliliter of purified erythrocytes
by magnetic bead depletion was performed using TRIZOL
(TRIzolH Reagent, Invitrogen) and subjected to the HIV-1 RNA
3.0 assay, in the RNA capture step. In order to determine whether
TRIZOL-mediated RNA extraction affects determination of viral
load, purified erythrocytes from HIV-negative individuals were
incubated with a known amount of two different viral strains (BaL
HIV-1 and HXB2 HIV-1), and subjected to viral load determi-
nation. This process did not affect viral load measurements (data
not shown).
Immunofluorescence
Purified erythrocytes were fixed with 4% p-formaldehyde in
PBS. Mouse anti-HIV-1 p24 Gag monoclonal antibody (NIH
AIDS Research & Reference Reagent Program) and goat anti-
mouse IgG-FITC (BD Biosciences) were used as primary and
secondary antibodies respectively. Samples were observed in a
Nikon Eclipse E200 (Plan1006, N.A. 1.35) epifluorescence
microscope. Purified erythrocytes from HIV-negative individuals
were incubated with tannic acid to allow antigen binding, then
incubated with recombinant p24-antigen (7,500 molecules of p24-
antigen/erythrocyte), and used as controls. The recombinant p24-
antigen used was the standard positive control of the Murex HIV
antigen Mab kit (Abbott). Fifteen different HIV-positive individ-
uals with plasma viral loads between 1,000 and 20,000 copies/ml
were used.
Flow-cytometry
In order to identify scatter properties of erythrocyte population
and to ensure the selection of the population of erythrocytes, we
stained 10
6 erythrocytes with glycophorin A, a major transmem-
brane sialoglycoprotein expressed on human erythrocyte mem-
brane. Afterwards, the erythrocytes were acquired in a flow
cytometer and used glycophorin A expression as a marker to define
forward and scatter detectors. Acquisition was set by forward/side
scatter detectors to logmode which providesbetterresolution. Once
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6 purified erythrocytes
from HIV-positive (n=7) or HIV-negative individuals were stained
with monoclonal anti-p24 (FITC-KC57, Coulter Clone, Hialeah,
FL) or control isotype antibody. 10
6 erythrocytes were stained with
five microlitres of pre-titrated FITC-KC57. The gate (P1) was
defined in the analysis to exclude all other cells and debris, based on
forward/scatter dot blot. Analysis was performed using a FACS
flow cytometer (FACSCanto, BD) and CellQuest software (BD
Biosciences, San Jose, CA). CD3+ CD4+ cells in the purified
erythrocytes fraction were counted by flow-cytometry (Coulter XL,
Coulter Co., Hialeah, FL).
Statistical analysis
Fisher’s Exact Test was used to calculate significance in
contingency tables, and the Chi-square test for trend was used to
evaluate tendencies. A p,0.05 was considered significant.
In all cases, the median and interquartile range (IQR) were
calculated considering only detectable values.
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